Atlas Trials

The Efficacy and Safety of TACE, Lenvatinib and Camrelizumab in the Treatment of BCLC Stage B/C Hepatocellular Carcinoma: a Single-arm, Single-center, Open-label Study

Clinical trial NCT04909866 · UNKNOWN

Trial details

NCT number
NCT04909866
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Status
UNKNOWN
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Hepatocellular Carcinoma
Start date
2021-01-01
Primary completion
2022-09-01
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.